George Voren is an associate at Flagship Pioneering. In this role, he works as part of a team of entrepreneurial scientists to conceive, create, resource and develop the next generation of Flagship’s first-in-category ventures, as well as to fund promising early-stage companies. George joined the firm after completing the firm's Fellows program.
Prior to joining Flagship, George received his Ph.D. in Neuropsychopharmacology from the Scripps Research Institute in Jupiter, FL and completed his dissertation research at the Mount Sinai School of Medicine in New York City, NY. He worked under Dr. Paul J. Kenny to investigate nicotine addiction and find novel therapeutic strategies for facilitating smoking cessation. His research lead to the first identified mammalian brain circuit that regulates nicotine craving during withdrawal.
While pursuing his Ph.D., George served as an in vivo scientist at Eolas Therapeutics, where he aided in the design, execution and analysis of behavioral experiments needed to successfully complete multiple preclinical milestones and earn funding extensions through the NIH Blueprint program for a new smoking cessation agent. Eolas is expected to begin the first in human trials with their lead compound in 2019. George also consulted early-stage startups at InSITE Fellows in New York City, where he worked with multiple young companies, including ReferWell, SolveBio and others.
George holds a bachelor’s degree in biotechnology from the University of Florida in Gainesville, FL, where he graduated magna cum laude. While pursuing his bachelor’s, he worked in the lab of Dr. Brian Cain, conducting research on hormone-mediated transcriptional regulation in the kidney that was published in 2012.